Published in N Engl J Med on December 14, 1989
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol (1994) 6.76
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol (2007) 3.58
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein. J Virol (1991) 2.77
Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci U S A (1997) 2.64
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol (1996) 2.50
Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 2.45
Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. J Clin Microbiol (1997) 2.37
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells. J Exp Med (1990) 2.13
Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A (1991) 2.12
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol (1992) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol (1993) 1.78
Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.76
HIV revealed: toward a natural history of the infection. N Engl J Med (1989) 1.66
Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 1.61
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1990) 1.55
Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci U S A (1993) 1.54
Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J Clin Microbiol (1993) 1.53
Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J Clin Invest (1991) 1.52
Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ (1991) 1.48
Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol (1990) 1.46
HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS (2009) 1.43
Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. J Clin Microbiol (1993) 1.40
Dangers of neonatal intubation with the Cole tube. BMJ (1990) 1.39
During HIV-1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion. Clin Exp Immunol (1992) 1.36
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. J Virol (1994) 1.36
Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol (1993) 1.35
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol (1995) 1.30
Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol (1995) 1.28
Replication of an acutely lethal simian immunodeficiency virus activates and induces proliferation of lymphocytes. J Virol (1991) 1.27
A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A (1996) 1.27
Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection. Clin Diagn Lab Immunol (1998) 1.25
Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J Virol (1994) 1.25
In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates. J Virol (1995) 1.24
Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system. J Clin Invest (1992) 1.20
Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev (1994) 1.19
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A (1990) 1.19
Dissociation of unintegrated viral DNA accumulation from single-cell lysis induced by human immunodeficiency virus type 1. J Virol (1992) 1.10
CD8+ T lymphocytes of African green monkeys secrete an immunodeficiency virus-suppressing lymphokine. Proc Natl Acad Sci U S A (1994) 1.09
Twin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitro. J Virol (1996) 1.08
Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med (1993) 1.08
Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction. J Clin Microbiol (1993) 1.07
Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J Virol (1996) 1.04
Human immunodeficiency virus type 1-infected individuals make autoantibodies that bind to CD43 on normal thymic lymphocytes. J Exp Med (1990) 1.04
Laboratory methods for early detection of human immunodeficiency virus type 1 in newborns and infants. Clin Microbiol Rev (1992) 1.04
Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression. EMBO J (1994) 1.04
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol (1994) 1.04
A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells. Proc Natl Acad Sci U S A (1993) 1.03
Quantitation of a lentivirus in its natural host: simian immunodeficiency virus in African green monkeys. J Virol (1992) 1.03
Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection. J Clin Microbiol (1994) 1.01
Changes in the cytopathic effects of human immunodeficiency virus type 1 associated with a single amino acid alteration in the ectodomain of the gp41 transmembrane glycoprotein. J Virol (1994) 0.99
Stability of infectious HIV in clinical samples and isolation from small volumes of whole blood. J Clin Pathol (1994) 0.98
Productive human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient. Proc Natl Acad Sci U S A (1990) 0.93
Recovery of the human immunodeficiency virus from fibreoptic bronchoscopes. Thorax (1991) 0.93
Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci U S A (1996) 0.92
Neutralization assay to resolve discrepancies between positive results in new highly sensitive anti-Toxoplasma gondii IgG assays and negative results in reference tests. Eur J Clin Microbiol Infect Dis (2010) 0.92
Similar replication capacities of primary human immunodeficiency virus type 1 isolates derived from a wide range of clinical sources. J Virol (1992) 0.88
Increased detection of human immunodeficiency virus antigenemia after dissociation of immune complexes at low pH. J Clin Microbiol (1993) 0.88
Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. J Virol (1998) 0.88
Survival of human immunodeficiency virus (HIV), HIV-infected lymphocytes, and poliovirus in water. Appl Environ Microbiol (1993) 0.88
Caveolin 1 inhibits HIV replication by transcriptional repression mediated through NF-κB. J Virol (2011) 0.87
HIV isolation from pulmonary cells derived from bronchoalveolar lavage. Clin Exp Immunol (1991) 0.87
Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract. PLoS One (2012) 0.86
Real-time PCR assay of individual human immunodeficiency virus type 1 variants in coinfected human lymphoid tissues. J Clin Microbiol (2003) 0.86
Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. Proc Natl Acad Sci U S A (1991) 0.84
Detection of p24 antigen with and without immune complex dissociation for longitudinal monitoring of human immunodeficiency virus type 1 infection. J Clin Microbiol (1995) 0.84
"One pill, once daily": what clinicians need to know about Atriplatrade mark. Ther Clin Risk Manag (2008) 0.83
Syphilis superinfection activates expression of human immunodeficiency virus I in latently infected rabbits. Am J Pathol (1991) 0.82
Virus load and sequence variation in simian retrovirus type 2 infection. J Virol (2000) 0.82
Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs. J Clin Invest (1991) 0.82
Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol (1998) 0.82
Detection of human immunodeficiency virus type 1 RNA in plasma samples from high-risk pediatric patients by using the self-sustained sequence replication reaction. J Clin Microbiol (1992) 0.81
Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci U S A (1996) 0.81
Relationship of HIV-1 provirus load, CD8+ CD11+ T cells and HIV-1 envelope-specific cytotoxic T lymphocytes in HIV-infected asymptomatic offients. Immunology (1994) 0.81
Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR. J Clin Microbiol (1996) 0.80
Modelling the course of an HIV infection: insights from ecology and evolution. Viruses (2012) 0.80
Relationship between frequency of infectious human immunodeficiency virus type 1-harboring cells and kinetics of viral replication: a simple procedure for quantitation of infectious virus-carrying cells in blood samples. J Clin Microbiol (1992) 0.79
Accumulation of activated CD4+ lymphocytes in the lung of individuals infected with HIV accompanied by increased virus production in patients with secondary infections. Clin Exp Immunol (1995) 0.79
Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol (2007) 0.79
Blood protein derivative viral safety: observations and analysis. Yale J Biol Med (1991) 0.79
Rapid culture and quantitation of human immunodeficiency virus type 1 from patient cells without the use of mitogen-stimulated donor cells. Clin Diagn Lab Immunol (1994) 0.79
Local differences in human immunodeficiency virus prevalence: a comparison of social venue patrons, antenatal patients, and sexually transmitted infection patients in eastern kinshasa. Sex Transm Dis (2009) 0.78
HIV type 1 fails to trigger innate immune factor synthesis in differentiated oral epithelium. AIDS Res Hum Retroviruses (2009) 0.78
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group. J Clin Microbiol (1996) 0.77
Effective use of frozen donor peripheral blood mononuclear cells for human immunodeficiency virus type 1 isolation from vertically infected pediatric patients. J Clin Microbiol (1994) 0.77
Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages. Antimicrob Agents Chemother (1993) 0.75
UV activation of human immunodeficiency virus gene expression in transgenic mice. J Virol (1992) 0.75
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Chronic fatigue in adolescents. Pediatrics (1991) 5.24
Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS (1988) 4.85
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med (2001) 4.26
Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol (1981) 4.10
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
The acquisition of herpes simplex virus during pregnancy. N Engl J Med (1997) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ (1994) 3.71
Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med (1988) 3.71
Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. Lancet (1987) 3.68
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med (1992) 3.56
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med (1993) 3.51
Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol (1999) 3.48
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med (1996) 3.35
Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med (1980) 3.33
Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med (1981) 3.32
Infections with herpes simplex viruses (1). N Engl J Med (1986) 3.26
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med (1991) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet (1986) 2.92
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis (2001) 2.79
Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med (1987) 2.74
Sexually transmitted diseases in victims of rape. N Engl J Med (1990) 2.74
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. J Infect Dis (1983) 2.60
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Chronic fatigue. A prospective clinical and virologic study. JAMA (1990) 2.54
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 2.53
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Typing of clinical herpes simplex virus isolates with mouse monoclonal antibodies to herpes simplex virus types 1 and 2: comparison with type-specific rabbit antisera and restriction endonuclease analysis of viral DNA. J Clin Microbiol (1983) 2.50
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med (1983) 2.33
Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med (1987) 2.32
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med (1992) 2.25
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med (1985) 2.23
Infections with herpes simplex viruses (2). N Engl J Med (1986) 2.22
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20
Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med (1987) 2.18
Retracted HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest (2000) 2.17
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol (1997) 2.16
Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med (1991) 2.12
Why don't patients and physicians talk about end-of-life care? Barriers to communication for patients with acquired immunodeficiency syndrome and their primary care clinicians. Arch Intern Med (2000) 2.09
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis (1999) 2.07
Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis (1991) 2.06
Epidemiology of Reye syndrome. Epidemiol Rev (1981) 2.04
Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA (1994) 2.03
Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion (1993) 2.03
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med (1989) 2.03
Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol (1999) 2.02
Monoclonal antibodies for diagnosis of infectious diseases in humans. Science (1983) 2.02
Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med (1993) 2.01
Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01